Powered By Google

Pillai Lab: Selected Publications


    2012

  • Leung W, Pui C, Coustan-Smith E, Yang J, Pei D, Gan K, Srinivasan A, Hartford C,Triplett B, Dallas M, Pillai A, Shook D, Rubnitz J, Sandlund J, Jeha S, Inaba H, Ribeiro R, Handgretinger R, Laver J, Campana D. Detectable minimal residual diseasebefore hematopoietic cell transplantation is prognostic but does not preclude cure for children with very- high-risk leukemia. Blood, 2012; in press.


  • 2011

  • Morales-Tirado V, Luszczek W, van der Merwe M, Pillai A. Regulatory immunotherapy in bone marrow transplantation. (Invited review). TSW Hematology 11:2620-2634, 2011. doi:10.1100/2011/768948 (www.tswj.com/2011/768948).

  • Leung W, Campana D, Yang J, Pei D, Coustan-Smith E, Gan K, Rubnitz J, Sandlund J, Ribeiro R, Srinivasan A, Hartford C, Triplett B, Dallas M, Pillai A, Handgretinger R, Laver J, Pui CH. High success of hematopoietic cell transplantation regardless of donor source in children with very-high-risk leukemia. Blood May 25, 2011.

  • Pillai A, Hartford C, Srinivasan A, Triplett B, Dallas M, Wang C, Yang J, Leung W. Favorable preliminary results using TLI/ATG-based immunomodulatory conditioning for matched unrelated donor allogeneic hematopoietic stem cell transplantation in pediatric severe aplastic anemia. Pediatric Transplantation July 15, 2011.


  • 2010

  • Pillai AB, Kohrt HJ, Lowsky R, Strober S. NKT cells, Treg, and their interactions in bone marrow transplantation. Eur J Immunol 40(7):1862-9, 2010.


  • 2009

  • Pillai A, George T, Dutt S, Strober S. Host natural killer T cells induce an IL-4 dependent expansion of donor CD4+CD25+Foxp3+ Tregs that protects against graft-versus-host disease. Blood 113(18):4458-67, 2009.


  • 2007

  • Pillai A, Teo P, George T, Mukhopadhyay A, Dejhbahksh-Jones S, Strober S. Alloantigen recognition is required for CD8-mediated graft anti-tumor activity against murine BCL1 lymphoma after myeloablative bone marrow transplantation. Bone Marrow Transplant 40 (5):487-97, 2007.

  • Pillai A, George T, Dutt S, Teo P, Strober S. Natural killer T cells can prevent graft-versus host-disease and permit graft anti-tumor activity after bone marrow transplantation. J Immunol 178 (10): 6242-51, 2007.


  • 1992

  • Clayberger C, Luna-Fineman S, Lee JE, Pillai A, Campbell M, Krensky AM. Interleukin-3 is a growth factor for human follicular B-cell lymphoma. J Exp Med 175 (2):371-6, 1992.